Adicet Bio (FRA:1IJ) Short Interest


FRA:1IJ Adicet Bio Inc FRA:1IJ
31 GF Score
Price €6.60
! 3 Warning Signs
View Full Analysis

What is Adicet Bio Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:1IJ vs CUE, TELO, AARD: Short Interest Comparison

For the Biotechnology subindustry, Adicet Bio's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adicet Bio Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's Short Interest distribution charts can be found below:

* The bar in red indicates where Adicet Bio's Short Interest falls into.


FRA:1IJ
31GF Score
Adicet Bio Inc FRA:1IJ
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adicet Bio Business Description

Other Exchanges ACET:USA0HX7:UK
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
31GF Score

Get the complete analysis for FRA:1IJ

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.60
Price